Search Beyond News…

Law firm Faruqi & Faruqi calls for lead plaintiffs in Capricor Therapeutics securities class action ahead of September 28 deadline

Executive summary: The law firm Faruqi & Faruqi is urging investors who suffered financial losses in Capricor Therapeutics to seek counsel before the September 28, 2026, deadline to lead a securities class action lawsuit. The appointment of a lead plaintiff is a decisive step in securities litigation that determines who will direct the settlement negotiations or trial proceedings, impacting how much recovery shareholders might receive.

Who is involved: Capricor Therapeutics, Inc. (NASDAQ: CAPR), Faruqi & Faruqi, LLP, and affected shareholders.

Likely next: The submission of lead plaintiff motions by interested investors before the September 28 deadline.

Faruqi & Faruqi, LLP has issued a formal solicitation for investors of Capricor Therapeutics (NASDAQ: CAPR) to organize a lead plaintiff group for a securities class action. This move follows reports of substantial investor losses and aims to establish a representative for the litigation. The deadline of September 28, 2026, serves as a critical procedural milestone for the potential lawsuit.

What's next — scenarios

Base Case: Lead plaintiff appointed (60%)

A lead plaintiff is formally recognized, and the class action proceeds toward discovery and potential settlement.

Downside: Lack of organized lead plaintiff (25%)

The litigation stalls or is handled by smaller, less influential firms, reducing the pressure on the company.

Upside: Rapid settlement agreement (15%)

Early movement in the litigation leads to a settlement before full trial proceedings, providing quicker but potentially smaller payouts.

What to watch

Timeline

Analysis — what this means

Likely next events

Sectors affected

Regulatory implications

Historical parallels

Key entities

Sources

Related cases

Browse the full archive →